Published 5 days ago • loading... • Updated 5 days ago
Haemonetics projects FY 2027 revenue growth of 4% to 7% as Persona PLUS rollout and IVT rebound efforts continue (NYSE:HAE)
Summary by Seeking Alpha
1 Articles
1 Articles
Haemonetics projects FY 2027 revenue growth of 4% to 7% as Persona PLUS rollout and IVT rebound efforts continue (NYSE:HAE)
Haemonetics (HAE) Q4 FY26 earnings call recap: revenue/EPS, FY27 guidance, Persona PLUS momentum, IVT inflection, and tariff risks—read now.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right1Center0Last Updated100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium
